{'fraction_non_alphanumeric': 0.036281179138321996, 'fraction_numerical': 0.027210884353741496, 'mean_word_length': 4.937219730941704, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Long-term administration of 3,5-diodo-4(3'-iodo4'-acetoxyphenoxy) benzoic acid (acetiromate) in hyperlipidemic patients.

A daily dose of 20-50mg of 3, 5-diiodo-4 (3'-iodo-4'-acetoxyphenoxy) benzoic acid (acetiromate) was given to four hyperlipidemic patients for a long period ranging from 2 years and 8 months to 5 years and 6 months. The compound was given initially in a daily dose of 10mg and the dose was gradually increased by 10-20mg every month until a satisfactory serum total cholesterol level was attained. The maintenance dose (20-40mg daily) was continued thereafter. The final serum cholesterol level showed a decline of 20.5 to 37.0% from the initial level. In a case of familiar hyperlipidemia, xanthomas disappeared after treatment. In another case, an attack of myocardial infarction took place during the treatment with a daily dose of 20mg. Otherwise, neither side effects nor changes in ECG were observed. In treating a large number of hyperlipidemia cases with thyroxine analogues for a long term, increased incidence of myocardial infarction must be seriously surveyed. Suppressed iodine uptake was considered to be caused by inorganic iodine freed from the compound. Serum thyroxine levels during the long-term treatment suggest no significant suppression in the thyroid function in these patients.